Why is CO₂ Becoming the Go-To Refrigerant for Pharmaceuticals?
For pharmaceutical decision-makers weighing every angle of a cooling strategy, CO₂ is increasingly touted as the refrigerant of choice for cold rooms. In recent years, CO₂ (R-744) has emerged as the preferred refrigerant for life science facilities that want the sustainability and efficiency benefits of a natural refrigerant without taking on the compliance and safety considerations of ammonia.
A Natural Refrigerant for Occupied Environments
CO₂ is non-flammable, non-toxic at typical operating concentrations, and widely accepted for use in occupied environments when properly engineered. These qualities align naturally with the clean, controlled spaces pharmaceutical manufacturing depends on.
Because CO₂ falls outside OSHA's Process Safety Management requirements, facilities avoid the formal PSM program and ammonia-specific compliance record keeping. That reduces administrative burden and long-term compliance costs, without requiring a facility to build out the specialized safety infrastructure that other systems may require.
Sustainability That Doesn’t Sacrifice Performance
CO₂ has zero ozone depletion potential and a global warming potential (GWP) of 1. Only ammonia, with a GWP of 0, ranks lower. For comparison, R-513a, one of the most common refrigerants in use, has a GWP of 573, meaning that it’s 573 times more harmful to the climate than a CO₂-based refrigeration solution.
The regulatory phasedown of HFCs is already well underway. The American Innovation and Manufacturing (AIM) Act of 2020 is a federal law that directs the U.S. Environmental Protection Agency to phase down the production and consumption of hydrofluorocarbons by 85% by 2036. With this regulatory target on the horizon, facility operators are arranging to future-proof their cooling systems sooner rather than later.
Now is the time to explore alternatives to outdated synthetic refrigerants, especially given the array of benefits that natural refrigerants offer. This is a meaningful consideration for any pharmaceutical manufacturer planning capital investment in cooling infrastructure that needs to perform for decades.
Performance That Meets Pharma's Standards
Sustainability and compliance simplicity mean little if a system can't deliver the performance pharmaceutical processes require. Innovative's approach to CO₂ is built around sustainable system designs and advanced control strategies that deliver the most reliable temperature uniformity across the entire cold box. This ensures that system performance goals are met across a variety of operating environments.
That engineering translates into high efficiency in low-temperature freezing and storage, stable performance across varying load conditions, and long-term reliability. Innovative’s cooling systems are also designed for effective integration with heat reclaim and rejection strategies, enabling higher COPs while simultaneously improving ESG compliance.
In warmer climates or highly variable environments, where CO₂ can otherwise lose ground on efficiency, system design and control strategy selection play a critical role in maintaining performance. This is exactly where Innovative's 30+ years of industrial refrigeration experience matters most.
CO₂ cooling systems can be configured to match a facility's specific needs. Innovative’s extensive experience ensures that we have a standard solution that can be tailored to any facility’s needs. Direct expansion (DX) systems deliver refrigerant straight to evaporators for responsive temperature control with simplified piping while pump recirculated systems, by contrast, offer more reliable performance through consistent liquid feed pressure and simpler control at the evaporator.
Are CO₂ Systems Compatible with Modular Design?
Whether installing in a greenfield site or expanding an existing facility, modular refrigeration systems offer a host of benefits. Time is saved, quality testing can be done offsite, and site impacts and risk are minimized. CO₂ refrigerant systems are ideal candidates for packaged and modular designs, making them compatible with the prefabricated construction approach that minimizes disruption to operating pharmaceutical facilities. Mechanical components can be manufactured and pressure-tested offsite, arriving ready for a tight installation window.
This offsite approach also supports the rigorous documentation pharma facilities require. Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT) can be built directly into the modular build process, and Innovative supports the full commissioning, qualification, and validation lifecycle — from CQV planning through IQ/OQ/PQ execution — backed by a complete turnover package (TOP) that gives your quality team the documentation trail they need from day one.
CO₂ isn't the answer for every application. In warmer climates, Ammonia and ammonia/CO₂ cascade cooling systems hold efficiency and cost advantages at scale, especially for central utility buildings.
Talk to a Pharma Process Cooling Expert Today
Choosing the right natural refrigerant requires a partner who understands both the engineering and the regulatory reality of the environment pharmaceutical manufacturing operates in.
